skip to content

Department of Oncology


Dr Bristi BasuJean Abraham



Research Interests

My research focus is in drug development and I translate preclinical findings on lead candidate agents into early phase clinical trials of novel therapeutic drugs as chief investigator, principal investigator and co-investigator in academic-led and industry-sponsored Phase I, II and III clinical trials, including first-in-human studies. My tumour site-specific focus is in hepato-pancreatico-biliary cancers, for which I am designing novel clinical trials based on preclinical research that has been performed at the Cambridge Pancreatic Cancer Centre. I am involved in projects of non-invasive imaging techniques that evaluate pharmacodynamic effects or show potential as early predictors for efficacy of anticancer drugs.


Pubmed journal articles - pubmed

Key publications

First-in-human pharmacokinetic and pharmacodynamic study of the dual m-TORC 1/2 inhibitor, AZD2014. Basu B*, Dean E*, Puglisi M, Greystoke A, Ong M, Burke W, Cavallin M, Bigley G, Womack C, Harrington EA, Green S, Oelmann E, de Bono JS, Ranson M, Banerji U. Clin Cancer Res. 2015 Aug 1;21(15):3412-9. doi: 10.1158/1078-0432.CCR-14-2422. *Joint first authors.

Combining Antiangiogenics to Overcome Resistance: rationale and clinical experience. Moreno Garcia V*, Basu B*, Molife R, Kaye S. Clinical Cancer Research 2012 Jul 15; 18(14): 3750-61 *Joint first authors.

Inhibition of MT1-MMP activity using functional antibody fragments selected against its hemopexin domain. Basu B, Correa-Sampaio P, Mohammed H, Fogarasi M, English W, Watkins N, Corrie P, Ouwehand W, Murphy G. International Journal of Biochemistry and Cell Biology 2012 Feb; 44(2): 393-403